Halozyme Therapeutic Expands Collaboration, License Deal With Argenx Over Development, Commercialization Of ENHANCE With Two Additional Targets
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize
Halozyme and Argenx agreed to work together on two more medicines. This shows both companies believe in their partnership and have more ideas to try.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.